Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis – results from multicenter observational cohort-Reference-Cited by-同舟云学术

Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis – results from multicenter observational cohort

Published:2018-10-09 Issue:11 Volume:18 Page:1181-1187
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Bálint Anita¹^ORCID,Rutka Mariann¹^ORCID,Kolar Martin²³^ORCID,Bortlik Martin²⁴,Duricova Dana²⁵,Hruba Veronika²,Lukas Martin²,Mitrova Katarina²⁶,Malickova Karin²⁶,Lukas Milan²,Szepes Zoltán¹^ORCID,Nagy Ferenc¹,Palatka Károly⁷,Lovas Szilvia⁷,Végh Zsuzsanna⁸,Kürti Zsuzsanna⁸,Csontos Ágnes⁹^ORCID,Miheller Pál⁹,Nyári Tibor¹⁰,Bor Renáta¹^ORCID,Milassin Ágnes¹^ORCID,Fábián Anna¹^ORCID,Szántó Kata¹^ORCID,Lakatos Péter L⁸,Molnár Tamás¹,Farkas Klaudia¹^ORCID

Affiliation:

1. 1st Department of Medicine, University of Szeged, Szeged, Hungary

2. IBD Clinical and Research Centre, Prague, Czech Republic

3. 1st Medical Faculty, Charles University, Prague, Czech Republic

4. Department of Internal Medicine, Military Hospital, Charles University, Prague, Czech Republic

5. Institute of Pharmacology, 1st Medical Faculty, Charles University, Prague, Czech Republic

6. Department of Paediatrics, Faculty Hospital Motol, 2nd Medical Faculty, Charles University, Prague, Czech Republic

7. Institute of Medicine, Department of Gastroenterology, University of Debrecen, Clinical Center, Debrecen, Hungary

8. First Department of Internal Medicine, Semmelweis University, Budapest, Hungary

9. Second Department of Internal Medicine, Semmelweis University, Budapest, Hungary

10. Department of Medical Physics and Informatics, University of Szeged, Szeged, Hungary

Funder

New National Excellence Program of the Ministry of Human Capacities

National Research, Development and Innovation Office

Foundation of University of Szeged

EFOP

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2018.1530758

Reference35 articles.

1. Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases

2. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort

3. Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort

4. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose Escalation Patterns of Advanced Therapies in Crohn’s Disease and Ulcerative Colitis: A Systematic Literature Review;Advances in Therapy;2023-03-17

2. Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis;Inflammatory Bowel Diseases;2022-11-01

3. Medical Management of Ulcerative Colitis;The ASCRS Textbook of Colon and Rectal Surgery;2021-11-21

4. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis;Journal of Clinical Medicine;2021-05-14

5. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases;Drugs;2020-01-30